Business Description
Windtree Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US97382D6004
Total Employee Number:
14Description
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | -0.73 | |||||
Debt-to-Equity | -1.11 | |||||
Debt-to-EBITDA | -0.3 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 92.9 | |||||
3-Year EPS without NRI Growth Rate | 82.7 | |||||
3-Year FCF Growth Rate | 77 | |||||
3-Year Book Growth Rate | -90.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 88.48 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.3 | |||||
9-Day RSI | 34.55 | |||||
14-Day RSI | 31.88 | |||||
3-1 Month Momentum % | -98.6 | |||||
6-1 Month Momentum % | -98.52 | |||||
12-1 Month Momentum % | -99.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.33 | |||||
Quick Ratio | 0.33 | |||||
Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -535 | |||||
Shareholder Yield % | 975 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1198.07 | |||||
ROA % | -150.47 | |||||
ROIC % | -49.04 | |||||
3-Year ROIIC % | -12.85 | |||||
ROC (Joel Greenblatt) % | -4196.49 | |||||
ROCE % | -313.25 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.3 | |||||
EV-to-EBITDA | -0.3 | |||||
EV-to-Forward-Revenue | 0.26 | |||||
EV-to-FCF | -0.84 | |||||
Earnings Yield (Greenblatt) % | -333.33 | |||||
FCF Yield % | -216014.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:WINT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Windtree Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -8.505 | ||
| Beta | 3.5229 | ||
| 3-Year Sharpe Ratio | -1.2 | ||
| 3-Year Sortino Ratio | -1.6 | ||
| Volatility % | 204.46 | ||
| 14-Day RSI | 31.88 | ||
| 14-Day ATR ($) | 0.00045 | ||
| 20-Day SMA ($) | 0.00033 | ||
| 12-1 Month Momentum % | -99.73 | ||
| 52-Week Range ($) | 0.0001 - 0.19 | ||
| Shares Outstanding (Mil) | 33.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Windtree Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Windtree Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 156 days | ||
| Third quarter earnings results for 2026 | 2026-11-19 | In 71 days | ||
| Second quarter earnings results for 2026 | 2026-09-09 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 0.06 (+1.55%) | ||
| Second quarter earnings results for 2025 | 2025-08-19 | 0.49 (-2.49%) | ||
| First quarter earnings results for 2025 | 2025-05-16 | 0.83 (-3.49%) | ||
| Annual report for 2024 | 2025-04-15 | 1.36 (+3.82%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-15 | 1.36 (+3.82%) | ||
| 0.02:1 Stock Split | 2025-02-21 | 4.80 (-4.00%) | ||
| Third quarter earnings results for 2024 | 2024-11-27 | 28.18 (+0.64%) |
Show
Entries
Windtree Therapeutics Inc Frequently Asked Questions
What is Windtree Therapeutics Inc(WINT)'s stock price today?
The current price of WINT is $0.00. The 52 week high of WINT is $0.19 and 52 week low is $0.00.
When is next earnings date of Windtree Therapeutics Inc(WINT)?
The next earnings date of Windtree Therapeutics Inc(WINT) is 2026-09-09 Est..
Does Windtree Therapeutics Inc(WINT) pay dividends? If so, how much?
Windtree Therapeutics Inc(WINT) does not pay dividend.
Press Release
Articles on Windtree Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers